title: Vasopressin V2-receptor antagonists: panaceas for hyponatremia?
abstract: The current treatment of hyponatremia is unsatisfactory and can be associated with significant morbidity. Vasopressin is inappropriately elevated in the majority of patients with hyponatremia and causes free water retention by stimulating V2-receptors in the collecting ducts. Recently, orally active, nonpeptide, selective vasopressin V2-receptor antagonists have been characterized and offer an exciting prospect for the treatment for hyponatremia. V2-receptor antagonists are effective aquaretic agents, that are capable of increasing free water clearance and plasma sodium and might be useful in the treatment of hyponatremia caused by syndrome of inappropriate secretion of antidiuretic hormone, heart failure, cirrhosis, and nephrotic syndrome. The rationale for their use and evidence from animal and human studies are discussed.
authors.affiliation: Division of Nephrology and Hypertension, Georgetown University Medical Center, Washington, DC 20007, USA. kitiyakc@medlib.georgetown.edu
authors.forename: C
authors.initials: C
authors.lastname: Kitiyakara
authors.forename: C S
authors.initials: CS
authors.lastname: Wilcox
mesh_terms: D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use; D006801:Humans; D007010:Hyponatremia / Q000188:drug therapy* / Q000378:metabolism; D009025:Morpholines / Q000627:therapeutic use*; D017483:Receptors, Vasopressin / Q000378:metabolism; D013141:Spiro Compounds / Q000627:therapeutic use*
chemical_list: D065092:Antidiuretic Hormone Receptor Antagonists; D001552:Benzazepines; D004232:Diuretics; D009025:Morpholines; D017483:Receptors, Vasopressin; D013141:Spiro Compounds; C076251:mozavaptan; C103281:satavaptan